Abstract:Objective To study the relationship between the chemokine CX3CL1/ CX3CR1 and platinum drug resistance, as well as prognosis in ovarian cancer patients. To dynamically detect the resistance nude mice model of CX3CL1 and its receptor CX3CR1 in the course of platinum resistance. To analyze the expression of CX3CL1, CX3CR1 and the correlation of Fas signaling pathway. Methods The cancer gene atlas(TCGA) database of patients with ovarian cancer genome-wide expression was employed to analyze the relation-ship of CX3CL1/ CX3CR1 in platinum sensitivity or resistant patients with clinical features. Ovarian cancer SKOV3 sensitive cells(SK-OV3-GFP) with green fluorescent marker and cisplatin resistant cells(SKOV3-GFP / DDPⅢ) were subcutaneously injected in nude mice. After xenograft was constracted, cisplatin was intraperitoneally injected. Real time fluorescence quantitative-PCR(qRT-PCR) was used to detect the expression of CX3CL1, CX3CR1 and genes on Fas signal pathway after 0, 2, 5, 8 times of cisplatin injection. Results CX3CL1 expression was negatively correlated with FIGO and platinum resistance(r=-0. 112,P= 0. 030;r=-0. 106,P= 0. 044), CX3CR1 expression was negatively correlated with progression-free survival time(r = -0. 130,P = 0. 029) and positively correlated with 1-year re-lapse rate(r= 0. 119,P = 0. 045). The average expression of CX3CL1 in platinum sensitive group was 3. 96±0. 039, higher than 3. 64± 0. 55 of platinum resistant group(P= 0. 000). After the intervention of cisplatin, xenograft grew gradually. The weight of xenograft in SK-OV3-GFP / DDPⅢ group was higher than SKOV3-GFP group, and xenograft in the both two groups shrank at the fifth time of infection. After cisplatin stimulation, the expression of CX3CL1/ CX3CR1 in SKOV3-GFP group increased significantly(P= 0. 001, P= 0. 002), but it remained low in SKOV3-GFP / DDPⅢ group. The expression of Fas and FADD of Fas signal pathway in SKOV3 GFP / DDPⅢ group was also significantly lower than them in SKOV3-GFP group(P<0. 001). However, PARP1 gene significantly rose in SKOV3GFP / DDPⅢgroup than that in SKOV3-GFP group(P<0. 001). The expression of CX3CL1 and CX3CR1 was positively correlated with Fas and FADD, while it was negatively correlated with PARP1 of Fas signaling pathways. Conclusion The down-regulation of CX3CL1 and CX3CR1 is associated with platinum resistance. They may play a role in maintain the sensitivity of tumor cells to platinum. The low expression of CX3CL1 and CX3CR1 may suppress Fas signal pathway through some mechanism, resulting in transduction disorder, inhibiting cell apop-tosis and inducing platinum resistance of ovarian cancer. The lower expression of drug-resistant cells may be a mechanism inhibiting Fas signaling pathways, which make its conduction misbalance, finally inhibiting cell apoptosis, inducing the resistance of ovarian cancer. It may be a platinum promote ovarian cancer therapy targeting molecules.

Rnai-Mediated Knockdown Of The Cln3 Gene Inhibits Proliferation And Promotes Apoptosis In Drug-Resistant Ovarian Cancer Cells

Efficient Inhibition of Ovarian Cancer by Short Hairpin RNA Targeting Claudin-3.

Effects of Lncrna ANRIL-knockdown on the Proliferation, Apoptosis and Cell Cycle of Gastric Cancer Cells.

Effect of CLN3 Silencing by RNA Interference on the Proliferation and Apoptosis of Human Colorectal Cancer Cells.

Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor.

Abstract 3582: Circular RNA Circplehm3 Acts As the Sponge of Microrna-9 to Suppress Ovarian Carcinoma Progression

Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.

The CLN3 gene is a novel molecular target for cancer drug discovery

MDR1 and MDR3 Genes and Drug Resistance to Cisplatin of Ovarian Cancer Cells

Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts

Antitumor Effects of Heparin-Polyethyleneimine Nanogels Delivering Claudin-3-targeted Short Hairpin RNA Combined with Low-Dose Cisplatin on Ovarian Cancer.

Shrna-Mediated Silencing Of The Rfc3 Gene Suppress Ovarian Tumor Cells Proliferation

Downregulation of NCL attenuates tumor formation and growth in HeLa cells by targeting the PI3K / AKT pathway

Chemokine CX3CL1/CX3CR1 biological axis promote ovarian cancer cell apotosis induced by platinum drug

Microrna184 Reverses Cisplatin Resistance in Human Ovarian Cancer Cells by Regulating the Phosphatidylinositol-3-Kinase (pi3k)/protein Kinase B (AKT) Signaling Pathway

Efficient Inhibition of Intraperitoneal Ovarian Cancer Growth in Nude Mice by Liposomal Delivery of Short Hairpin RNA Against STAT3

SLC1A3 knockdown in inhibiting the proliferation, apoptosis resistance, and migration of ovarian cancer cells

RNA Interference-Mediated Silencing of the Phosphatidylinositol 3-Kinase Catalytic Subunit Attenuates Growth of Human Ovarian Cancer Cells in Vitroand in Vivo.

Influence of Silencing Clusterin by RNAi on Radiosensitivity of Human Ovarian Carcinoma SKOV3 Cell-Line

CircPLEKHM3 Acts As a Tumor Suppressor Through Regulation of the Mir-9/Brca1/dnajb6/klf4/akt1 Axis in Ovarian Cancer.

RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells.